 CAMBRIDGE, Mass., Jan. 04, 2021 GLOBE NEWSWIRE -- Cyclerion Therapeutics, Inc. Nasdaq: CYCN, a clinical-stage biopharmaceutical company developing innovative medicines for people with serious diseases of the central nervous system CNS, today announced that it will present a corporate overview at upcoming investor conferences: 